尼古丁胺补充剂对正常血压玻璃眼的作用:一个交叉的安慰剂控制的随机临床试验
Ahnul Ha1, Young Kook Kim2, Chang Kyu Lee3
1Department of Ophthalmology, Jeju University Hospital, Jeju University, Jeju, Republic of Korea.
The British journal of ophthalmology
|October 30, 2025
概括
尼古丁胺胺 (NAM) 补充剂在正常张力玻璃眼 (NTG) 患者中改善了视网膜功能. 口服NAM增强了电网膜学测量,这表明NTG的潜在神经保护益处.
科学领域:
- 眼科医生 眼科 眼科
- 神经科学是一个神经科学.
- 临床试验 临床试验
背景情况:
- 尼古丁胺 (NAM) 在各种模型中显示出神经保护作用.
- 正常张力玻璃眼 (NTG) 的特点是视神经损伤,尽管正常的眼内压力 (IOP).
- 之前的研究表明,NAM在眼部疾病中的潜在益处.
研究的目的:
- 评估口服尼古丁胺胺 (NAM) 补充剂在改善正常张力玻璃眼 (NTG) 患者视网膜功能方面的疗效.
- 评估NAM对接受IOP降压治疗的NTG患者的电生理学和视野测量的影响.
主要方法:
- 一个双面罩,安慰剂控制的交叉随机临床试验,涉及53名NTG参与者.
- 参与者接受了口服安慰剂或NAM (1g/天6周,然后2g/天6周),没有洗期.
- 视网膜功能使用全场电网膜学 (ERG) 和视野测试进行评估.
主要成果:
- 与安慰剂相比,在NAM组中观察到峰值至低谷 (PhNRPT) 和B波幅的光学负响应显著改善.
- 在NAM组 (29.0%) 与安慰剂组 (19.3%) 相比,PhNRPT的改善显著更多.
- 两组之间视野指数 (平均偏差,模式SD,视野指数) 没有发现显著差异.
结论:
- 在NTG参与者中,口服NAM补充诱导了视网膜电生理学 (PhNRPT和B波) 的功能改善.
- 这些发现表明NAM在NTG中具有潜在的神经保护作用.
- 需要进一步的长期研究来证实NAM在NTG群体中的有效性,因为它们具有独特的疾病特征.
相关概念视频
Open Angle Glaucoma: Treatment
951
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
951
Angle Closure Glaucoma: Treatment
1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
Glaucoma: Overview
1.2K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.2K
Hypertension III: Clinical Manifestations and Diagnostic Studies
457
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
457
Bioavailability Study Design: Healthy Subjects Versus Patients
140
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
140
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K


